AbbVie Inc. ABBV

ABBV Company Overview

AbbVie Inc. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing medicines and therapies across immunology, oncology, neuroscience, aesthetics, and eye care. The company was formed in 2013 as a spin-off from Abbott Laboratories and operates within the broader pharmaceutical and biotechnology industries. AbbVie’s primary revenue drivers include immunology therapies such as Humira, Skyrizi, and Rinvoq; neuroscience products including Botox Therapeutic and Vraylar; oncology treatments such as Imbruvica and Venclexta; and aesthetics products led by Botox Cosmetic and Juvederm. The company serves hospitals, physicians, specialty clinics, healthcare systems, pharmacies, and patients globally.

AbbVie has positioned itself as a diversified biopharmaceutical company with a strong commercial footprint and significant research and development capabilities. Historically, Humira was the company’s dominant product and among the world’s highest-grossing pharmaceuticals, but AbbVie has strategically shifted toward newer immunology products and diversified therapeutic categories following biosimilar competition in major markets. The acquisition of Allergan in 2020 substantially expanded AbbVie’s medical aesthetics, neuroscience, and eye care businesses, broadening its revenue base and global reach.